期刊文献+

文拉法辛与米氮平治疗急性期抑郁症的对照研究 被引量:2

Controlled Study on Venlafaxine and Mirtazapine on the Treatment of Depression in Acute Period
原文传递
导出
摘要 目的比较文拉法辛与米氮平对急性期抑郁症患者的起效时间、疗效和安全性。方法将64例急性期抑郁症患者随机分为两组,分别以文拉法辛与米氮平(各32例)治疗8周。用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)评价疗效和不良反应,以治疗1周末HAMD减分率≥20%评定起效时间。结果两组患者HAMD评分从第1周末起明显下降(P<0.01),文拉法辛组治疗1周末HAMD减分率≥20%25例(78.1%);米氮平组23例(71.8%),两组起效时间比较无显著性差异(P>0.050)。治疗8周末文拉法辛显效率75%,米氮平组为78.1%,两组疗效相当。副反应量表(TESS)比较无显著性差异(P>0.05)。结论文拉法辛与米氮平治疗急性期抑郁症起效迅速、疗效肯定,不良反应轻微,安全性好。 Objective To compare the works of time,efficacy and safety of venlafaxine and mirtazapine of on the treatment of patients with depression in the acute phase. Methods A total of 64 patients with depression in the acute period were randomly divided into two groups, they took venlafaxine or mirtazapine (all 32 cases)for 8 weeks. Using Hamilton depression rating scale (HAMD)and side effects scale(TESS)to therapeutic evaluation and adverse reaction to treatment on a weekend HAMD deducted rate quartile 20% for work of time. Results The HAMD scores of two groups of patients from the first weekend declined significantly (P〈0. 01) ,There were 25 cases of venlafaxine treatment group on a weekend HAMD whose reducing scores were more than 20%(78. l%);and 23 cases of mirtazapine group(71.8%),they had no significant difference(P〉0. 050). At 8 weekend after treatment,significant efficiency was 75 % in venlafaxine group and 78.1 %in mirtazapine group,, there was no significant difference in side effects scale(TESS)(P〉0.05). Conclusion Venlafaxine and mirtazapineon the treatment of depression in acute period arc workin~ a uicklv,effective ,mild adverse reactions,Rood safetv.
出处 《中国健康心理学杂志》 2012年第7期974-975,共2页 China Journal of Health Psychology
关键词 文拉法辛 米氮平 急性期抑郁 疗效 Venlafaxine Mirtazapine Depression in acute period Curative effect
  • 相关文献

参考文献3

二级参考文献11

  • 1陈青松.米氮平与氟西汀治疗抑郁症对照研究[J].中国健康心理学杂志,2005,13(1):25-26. 被引量:3
  • 2李秀娥.文拉法辛治疗抑郁症疗效观察(附20例临床分析)[J].中国健康心理学杂志,2005,13(4):263-264. 被引量:3
  • 3国效峰,赵靖平,陈晋东.度洛西汀:一种新型抗抑郁药[J].中国新药与临床杂志,2006,25(7):552-555. 被引量:89
  • 4张述杰,王美娟,胡君,赵路平,张蕙兰.文拉法辛与帕罗西汀治疗抑郁症对照研究[J].中国健康心理学杂志,2006,14(6):644-645. 被引量:11
  • 5Nierenberg AA, Greis JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non - inferiority study. Curr Med Res Opin, 2007,23(2) : 401 -416.
  • 6Hirschfeld RM, Mallinckrodt C, Lee TC, et al. Time course of depression- symptom improvement during treatment with duloxetine. Depress Anxiety, 2005, 21 ( 4 ) : 170 - 177.
  • 7Perahia DC, Wang F, Erl Wood, et al. Duloxetine in the treatment of major depressive disorder: a placebo - and paroxetine -controlled trial. Eur Psychiatry, 2006, 21 (6) :367 - 378.
  • 8Bailey RK, Mallinckrodt CH, Wohlreich MM, et al. Duloxetine in the treatment of major depressive disorder: comparison of safety and efficacy. J Natl Med Assoc, 2006, 98(5) :457 -447.
  • 9Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine - XR in the treatment of major depressive disorder: a meta - analysis of randomized clinical trials. Ann Pharmacother, 2005,39 ( 11 ) : 1798 - 1807.
  • 10袁勇贵,张心保.新型抗抑郁药米氮平[J].中国新药与临床杂志,2001,20(3):219-221. 被引量:52

共引文献81

同被引文献12

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部